August 12, 2005
Emory U. Sells Rights to AIDS Drug, Betting on an Immediate Payoff
Article: Missed ChancesEmory University took a bit of a gamble when it decided last month to sell its rights to future royalties on anti-AIDS drugs. But with a sure payoff of more than a half-billion dollars, university officials said it seemed like a worthy risk.
Under the terms of the deal, the university received a total of $525-million from two companies, Gilead Sciences Inc. and Royalty Pharma. Gilead is a drug
This is an article for subscribers only. You may access this article by purchasing a:
Digital or Print Subscription
Web Pass
Already have an account? Log In Now.
-
Peer Review

-
Academic Assets

-
Teaching


